Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trial

BMC Psychiatry

Zhonglin Liu¹  Songhua Xiao¹  Jun Liu¹  Xiaoming Rong¹  Jingyang Hu¹  Zhuoyuan Zhong¹  Limin Wang² 

[1] Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China;Department of Neurology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Neuroscience Institute, Guangzhou, 510080, Guangdong Province, P P China

关键词: Chronic somatic diseases;    Depression and anxiety;    Deanxit;    Sertraline;   

Others  :  1177238
DOI  :  10.1186/s12888-015-0449-2

 received in 2014-10-14, accepted in 2015-03-19,  发布年份 2015

【 摘 要 】

Background

Patients in chronic somatic diseases are often accompanied with depression and anxiety, remission of which may be observed in the third or fourth week after applying common antidepressant medications. We investigate the efficacy and safety of sertraline plus deanxit on patients with depression and anxiety in chronic somatic diseases.

Methods

75 Patients who met the criteria were randomly assigned to deanxit group or placebo group: sertraline (75 mg/day) plus deanxit (one piece/day) (N = 38), or sertraline (75 mg/day) plus placebo (one piece/day) (N = 37) for 2 weeks, both groups received sertraline (75 mg/day) in the following 2 weeks. Changes from baseline to day 4, day 8, day 15, and day 29 in Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) total scores were the efficacy measures. Adverse events were monitored and registered systematically during the trial.

Results

Response rates for HAM-D scores in deanxit group and placebo group were significantly different on day 8(55.26% ± 2.56% VS 24.32% ± 2.19%, p = 0.006) and day 15(78.95% ± 3.89% VS 40.54% ± 4.18%, p = 0.001), while no statistical differences were observed on day 4 and day 29. Respectively, response rates for HAM-A scores on day 4 (34.21% ± 2.21% VS 8.11% ± 1.37%, p = 0.006), day 8 (57.89% ± 3.56% VS 18.92% ± 2.68%, p = 0.001) and day 15 (78.95% ± 4.37% VS 43.24% ± 4.68%, p = 0.002), favoring the deanxit group. However, HAM-A scores were not remarkably different at the end point. The overall safety profile of both groups was favorable with no distinct differences.

Conclusions

The efficacy was exhibited in the deanxit group, with evidence for similar safety. The rapid onset of sertraline plus short-term deanxit indicated that it might be an inspiring strategy to manage depression and anxiety within the first two weeks in chronic somatic diseases.

【 授权许可】

   
2015 Wang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jeong S, Youn CH, Shim EB, Kim M, Cho YM, Peng L: An integrated healthcare system for personalized chronic disease care in home-hospital environments. IEEE Trans Inf Technol Biomed 2012, 16:572-85.
• [2]Truglio J, Graziano M, Vedanthan R, Hahn S, Rios C, Hendel-Paterson B, et al.: Global health and primary care: increasing burden of chronic diseases and need for integrated training. Mt Sinai J Med 2012, 79:464-74.
• [3]Stojanović-Tasić M, Grgurević A, Cvetković J, Grgurević U, Trajković G: Association between somatic diseases and symptoms of depression and anxiety among Belgrade University students. Med Glas (Zenica) 2014, 11(2):373-8.
• [4]Bhattacharya R, Shen C, Sambamoorthi U: Excess risk of chronic physical conditions associated with depression and anxiety. BMC Psychiatry 2014, 14:10. BioMed Central Full Text
• [5]Jones JD, Butterfield LC, Song W, Lafo J, Mangal P, Okun MS, et al. Anxiety and Depression Are Better Correlates of Parkinson’s Disease Quality of Life Than Apathy. J Neuropsychiatry Clin Neurosci. 2014;Aug 27. doi: 10.1176/appi.neuropsych.13120380. (http://dx.doi.org.ezp.lib.unimelb.edu.au/10.1176/appi.neuropsych.13120380).
• [6]Blakemore A, Dickens C, Guthrie E, Bower P, Kontopantelis E, Afzal C, et al.: Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2014, 20(9):501-12.
• [7]Sagna A, Gallo JJ, Pontone GM: Systematic review of factors associated with depression and anxiety disorders among older adultswith Parkinson’s disease. Parkinsonism Relat Disord 2014, 20(7):708-15.
• [8]Doyle T, Palmer S, Johnson J, Babyak MA, Smith P, Mabe S, et al.: Association of anxiety and depression with pulmonary-specific symptoms in chronic obstructive pulmonary disease. Int J Psychiatry Med 2013, 45(2):189-202.
• [9]Trento M, Trevisan M, Raballo M, Passera P, Charrier L, Cavallo F, et al.: Depression, anxiety, cognitive impairment and their a ssociation with clinical and demographic variables in people wit h type 2 diabetes: a 4-year prospective study. J Endocrinol Invest 2014, 37(1):79-85.
• [10]Kretchy IA, Owusu-Daaku FT, Danquah SA: Mental health in hypertension: assessing symptoms of anxiety, depression and stress on anti-hypertensive medication adherence. Int J Ment Health Syst 2014, 21:8-25.
• [11]Ganasegeran K, Renganathan P, Manaf RA, Al-Dubai SA: Factors associated with anxiety and depression among type 2 diabetes outpatients in Malaysia: a descriptive cross-sectional single-centre study. BMJ Open 2014, 4:e004794.
• [12]Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-58.
• [13]Sheehan DV, Kamijima K: An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol 2009, 24:43-60.
• [14]Frazer A, Benmansour S: Delayed pharmacological effects of antidepressants. Mol Psychiatry 2002, 7(Suppl 1):S23-8.
• [15]Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, et al.: Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Aliment Pharmacol Ther 2008, 27:1148-55.
• [16]Zhang Y, Becker T, Kösters M: Preliminary study of patterns of medication use for depression treatment in China. Asia Pac Psychiatry 2013, 5:231-6.
• [17]Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC: Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62:1217-27.
• [18]Gelenberg AJ, Chesen CL: How fast are antidepressants? J Clin Psychiatry 2000, 61:712-21.
• [19]Hsu JW, Su TP, Huang CY, Chen YS, Chou YN: Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naive first-episode major depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study. J Clin Psychopharmacol 2011, 31:577-81.
• [20]Stegenga BT, Nazareth I, Torres-Gonzalez F, Xavier M, Svab I, Geerlings MI, et al.: Depression, anxiety and physical function: exploring the strength of causality. J Epidemiol Community Health 2012, 66:e25.
• [21]Yohannes AM, Alexopoulos GS: Depression and anxiety in patients with COPD. Eur Respir Rev 2014, 23:345-9.
• [22]Huang X, Li C, Li WH, Luo YL, Wang B, Zhang W, et al.: Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial. Hum Psychopharmacol 2013, 28:594-9.
• [23]Gois C, Dias VV, Carmo I, Duarte R, Ferro A, Santos AL: Treatment response in type 2 diabetes patients with major depression. Clin Psychol Psychother 2014, 21:39-48.
• [24]Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, et al.: Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006, 63:521-9.
• [25]Mokhber N, Abdollahian E, Soltanifar A, Samadi R, Saghebi A, Haghighi MB, et al.: Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry 2014, 47:131-40.
• [26]Yang R, Zhang H, Wu X, Yang J, Ma M, Gao Y, et al.: Hypothalamus-anchored resting brain network changes before and after sertraline treatment in major depression. Biomed Res Int 2014, 2014:915026.
• [27]Al-Amin MM, Uddin MM, Rahman MM, Reza HM, Rana MS: Effect of diclofenac and antidepressants on the inflammatory response in astrocyte cell culture. Inflammopharmacology 2013, 21:421-5.
• [28]Taraz M, Khatami MR, Dashti-Khavidaki S, Akhonzadeh S, Noorbala AA, Ghaeli P, et al.: Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. Int Immunopharmacol 2013, 17:917-23.
• [29]Kaulmann A, Bohn T: Carotenoids, inflammation, and oxidative stress-implications of cellular signaling pathways and relation to chronic disease prevention. Nutr Res 2014, 34(11):907-29.
• [30]Hostmaelingen HJ, Asskilt O, Austad SG, Fjellheim J, Høstmaelingen EA, Kristiansen PH, et al.: Primary care treatment of depression in the elderly: a double-blind, multi-centre study of flupenthixol (‘Fluanxol’) and sustained-release amitriptyline. Current Med Res Opinion 1989, 11:593-9.
• [31]Majid I: A double-blind comparison of once-daily flupenthixol and mianserin in depressed hospital out-patients. Pharmatherapeutica 1986, 4:405-10.
• [32]Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A: Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol. Acta Psychiatr Belg 1983, 83:525-39.
• [33]Yu YY, Fang DC, Fan LL, Chang H, Wu ZL, Cao Y, et al.: Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders. J Gastroenterol Hepatol 2014, 29:1200-6.
• [34]Kao Y-C, Shiah I-S, Lee W-K, Kuo S-C, Huang C-C, Ku Y-C: Deanxit-associated tardive dyskinesia and tardive akathisia in a depressed patient. Acta Neuropsychiatrica 2010, 22:47-8.